M&A Deal Summary |
|
|---|---|
| Date | 2024-04-02 |
| Target | Modulus Therapeutics - Cell Therapy Assets |
| Sector | Life Science |
| Buyer(s) | Ginkgo Bioworks |
| Sellers(s) | Modulus Therapeutics |
| Deal Type | Divestiture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2008 |
| Sector | Life Science |
Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks was established in 2008 and is based in Boston, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 14 of 14 |
| Sector (Life Science) | 9 of 9 |
| Type (Divestiture) | 3 of 3 |
| State (Washington) | 1 of 1 |
| Country (United States) | 11 of 11 |
| Year (2024) | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-02-28 |
Proof Diagnostics
Cambridge, Massachusetts, United States Proof Diagnostics is a life sciences tools, diagnostics, and computational discovery company that uncovered genome engineering tools for both therapeutic and diagnostics applications while developing a smart, portable system for the detection of infectious and other diseases. Proof Diagnostics was founded in 2020 and is based in Cambridge, Massachusetts. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 2020 |
| Sector | Life Science |
Modulus Therapeutics is a cell engineering company focused on the design of next-generation cell therapies for autoimmune diseases. Modulus Therapeutics was formed in 2020 and is based in Seattle, Washington.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| State (Washington) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2024) | 1 of 1 |
